Atrial Fibrillation: A Global Strategic Business Report
San Jose, CA (Vocus) August 19, 2010
Atrial fibrillation (AF), the commonly occurring cardiac rhythm disturbance, is a potentially life-threatening condition, which is gradually becoming an expensive medical ailment, placing a significant burden on hospitals, healthcare providers, patients, and the overall healthcare system. Atrial fibrillation is considered to be the precursor to various serious cardiovascular complications such as stroke, with the likelihood of strokes in patients suffering from atrial fibrillation increasing by about 5 times. About 800 thousand people suffer from stroke annually in the US, with occurrence of about 200 thousand cases of fatal strokes recorded per annum. The increasing costs of treating such cardiovascular complications has propelled the medical community to focus on the treatment for atrial fibrillation, resulting in unprecedented expansion of the treatment options through both therapeutics and devices.
Though therapeutics have been previously considered to be the ideal treatment, drugs for treating atrial fibrillation have been associated with serious side effects in few patients. Ineffectiveness of drugs is another major concern related to the therapeutics for AF, as more than half of the patients remain uncured during the initial years of therapy. To counter these limitations of drugs therapy, other non-drug treatments including catheter ablation, implantable devices, cardioversion and surgical ablation are finding an acceptable market for AF treatment.
Diagnostics account for a major share of the atrial fibrillation market, accounting for more than 25% share of the global market, as stated by a new market research report on Atrial Fibrillation. With the increase in number of catheter ablation procedures as a treatment option for AF, ablation catheter market is projected to register a CAGR of about 13% over the analysis period. In addition, increasing number of steerable diagnostic EP catheters are now equipped with mapping technology. Mapping catheters are more sophisticated in nature and hence command higher prices than non-mapping catheters.
In terms of therapeutics, new anticoagulants such as Boehringer Ingelheim's Pradaxa/Rendix, Bristol-Myers Squibb/Pfizer's Apixaban, and Bayer/Johnson & Johnson's Xarelto are expected to command a major share of the overall atrial fibrillation drugs market in the coming years. The ability to prevent stroke, safety and convenience are the major factors driving growth of such anticoagulants. The introduction and massive popularity of Multaq, an antiarrhythmic drug from Sanofi-aventis, along with expanded usage of new anticoagulants, are expected to drive market expansion.
Major players profiled in the report include AtriCure Inc., Baxter International, Becton, Dickinson & Company, Biosense Webster Inc., Boston Scientific Corp., Cardiome Pharma Corp., C.R. Bard Inc., Cardima Inc., Endosense SA, Medtronic Inc., Sanofi-Aventis, Sorin SpA, Spectrasonics Inc., St. Jude Medical Inc., and Zimmer Holdings Inc.
The report titled “Atrial Fibrillation: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a strategic focus on the global Atrial Fibrillation market, current market trends, future prospects, the disease overview, various therapeutics indicated for atrial fibrillation, ablation catheters, new product introductions, recent industry activity, and profiles of market players worldwide. The report analyzes market data and analytics in terms of value for the overall global market. Product segments analyzed include Advanced Mapping, Ablation Catheters, Surgical Ablation Devices, Introducers & Accessories, and Diagnostics. The report also analyzes the market revenues of Atrial Fibrillation Therapies.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Atrial_Fibrillation_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/